Curis, Inc. Announces Presentation of CUDC-427 and Erivedge® Clinical Results at American Society of Clinical Oncology Annual Meeting

Published: May 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that a clinical abstract reporting Phase I clinical results of CUDC-427, a small molecule antagonist of IAP proteins, has been selected for oral presentation at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), being held from May 31- June 4 in Chicago, IL.

Help employers find you! Check out all the jobs and post your resume.

Back to news